Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Huilei Miao"'
Autor:
Huiyao Huang, Shuopeng Jia, Xin Wang, Huilei Miao, Hong Fang, Hanqing He, Dawei Wu, Yu Tang, Ning Li
Publikováno v:
Thoracic Cancer, Vol 15, Iss 14, Pp 1187-1194 (2024)
Abstract Introduction Restrictive eligibility criteria in cancer drug trials result in low enrollment rates and limited population diversity. Relaxed eligibility criteria (REC) based on solid evidence is becoming necessary for stakeholders worldwide.
Externí odkaz:
https://doaj.org/article/9a7df16946554f71a18e8f79aa451014
Autor:
Huiyao Huang, Yu Tang, Yue Yu, Anqi Yu, Dawei Wu, Hong Fang, Shuhang Wang, Chao Sun, Xin Wang, Qi Fan, Yuan Fang, Qiyu Tang, Ning Jiang, Jingting Du, Huilei Miao, Ying Bai, Peiwen Ma, Shujun Xing, Dandan Cui, Shuangman Miao, Yale Jiang, Jingxiao Zhu, Qi Zhu, Ye Leng, Lan Wei Guo, Shanmei Liao, Yaguang Shao, Yinyin Song, Zeyuan Liu, Minghuang Hong, Suxia Luo, Binghe Xu, Gongtao Lan, Ning Li
Publikováno v:
The Lancet Regional Health. Western Pacific, Vol 31, Iss , Pp 100624- (2023)
Summary: Overall survival (OS) is considered the standard clinical endpoint to support effectiveness claims in new drug applications globally, particularly for lethal conditions such as cancer. However, the source and reliability of OS in the setting
Externí odkaz:
https://doaj.org/article/3ab02991cce14189a287c6d0d11b5e87
Autor:
Shuhang Wang, Yuqi Yang, Peiwen Ma, Huiyao Huang, Qiyu Tang, Huilei Miao, Yuan Fang, Ning Jiang, Yandong Li, Qi Zhu, Wei Tao, Yan Zha, Ning Li
Publikováno v:
Molecular Therapy: Oncolytics, Vol 24, Iss , Pp 799-813 (2022)
Tumor-associated macrophages (TAMs) exert integrated effects in all aspects of tumor progression, including tumor cell proliferation, angiogenesis, invasion, and metastasis. Recently, considerable preclinical and clinical trials have demonstrated tha
Externí odkaz:
https://doaj.org/article/5916967ceeb548f4917300a56f89afbe
Autor:
Dawei Wu, Huiyao Huang, Minghui Zhang, Ziwei Li, Shuhang Wang, Yue Yu, Yuan Fang, Ning Jiang, Huilei Miao, Peiwen Ma, Yu Tang, Ning Li
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-4 (2022)
Abstract The neoadjuvant and adjuvant anti-PD-1/PD-L1 treatment has been increasingly noticed. To summarize the global landscape of these clinical trials will provide essential data for all the stakeholders of drug development. Based on the Trialtrov
Externí odkaz:
https://doaj.org/article/11990d94452e40599aebebaa00007503
Autor:
Shuhang Wang, Yale Jiang, Huilei Miao, Yuan Fang, Ning Jiang, Yue Yu, Peiwen Ma, Qiyu Tang, Dandan Cui, Hong Fang, Huiyao Huang, Qi Fan, Chao Sun, Anqi Yu, Shuangman Miao, Jingting Du, Jingxiao Zhu, Yuning Wang, Ning Li
Publikováno v:
EMBO Molecular Medicine, Vol 15, Iss 1, Pp n/a-n/a (2023)
Rare tumor has a huge unmet medical need without standard regimens, calling for novel therapeutic interventions. The National Cancer Center of China identified a threshold of incidence for rare tumor as 2.5/100,000, based on the characteristics of Ch
Externí odkaz:
https://doaj.org/article/1aec64bcd68642c58834e7e40261dcc9
Autor:
Huiyao Huang, Huilei Miao, Jun Wang, Dawei Wu, Qi Lei, Shuhang Wang, Hong Fang, Yu Tang, Ning Li, Binghe Xu, Jie He
Publikováno v:
Journal of the National Cancer Center, Vol 1, Iss 4, Pp 147-152 (2021)
Objectives: To describe and compare the research and development (R&D) pipeline of cancer new drugs and newly approved drugs in China and the USA in 2020, thus to provide decision-making evidence for related stakeholders. Methods: Clinical trials and
Externí odkaz:
https://doaj.org/article/d8b2537297774b9ca2ba38c8b3a18a4a
Autor:
Ning Jiang, Yue Yu, Min Zhang, Yu Tang, Dawei Wu, Shuhang Wang, Yuan Fang, Yu Zhang, Lin Meng, Yingying Li, Huilei Miao, Peiwen Ma, Huiyao Huang, Ning Li
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundIn recent years, significant progress has been made in immune checkpoint inhibitors (ICIs). However, accompanied by remarkable efficacy, a growing number of immune-related adverse events (irAEs) also arose. The mechanism of irAEs remains un
Externí odkaz:
https://doaj.org/article/a2770d3eac854bdead76b17a3cb831de
Autor:
Shiyu Zhang, Jiaxing Song, Yuyan Yang, Huilei Miao, Lu Yang, Yuehua Liu, Xue Zhang, Yaping Liu, Tao Wang
Publikováno v:
Pediatric Rheumatology Online Journal, Vol 19, Iss 1, Pp 1-8 (2021)
Abstract Background Type I interferonopathies are a group of rare autoimmune diseases characterised by excessive activation of type I interferon that leads to disturbances in immune function. Three prime repair exonuclease 1 (TREX1) is an important e
Externí odkaz:
https://doaj.org/article/cc5cd8cdd6f4424c86122fb35818ebf9
Autor:
Shuhang Wang, Qin Li, Peiwen Ma, Yuan Fang, Yue Yu, Ning Jiang, Huilei Miao, Qiyu Tang, Yuqi Yang, Shujun Xing, Rongrong Chen, Xin Yi, Ning Li
Publikováno v:
Frontiers in Molecular Biosciences, Vol 9 (2022)
KRAS is the most commonly mutated oncogene in human cancers. Targeted therapy and immunotherapy for this gene have made remarkable progress in recent years. However, comprehensive molecular landscape analysis of KRAS in rare tumors is lacking. Retros
Externí odkaz:
https://doaj.org/article/a3e8ad11aa784b759a549f7b4fdfc804
Bone mineral density and bone microarchitecture in a cohort of patients with Erdheim-Chester Disease
Autor:
Tianhua He, Lijia Cui, Na Niu, Fengdan Wang, Huilei Miao, Hao Zhao, Xuemin Gao, Chang Liu, Fan Yu, Yan Jiang, Ou Wang, Mei Li, Xiaoping Xing, Daobin Zhou, Jian Li, Xinxin Cao, Weibo Xia
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 15, Iss 1, Pp 1-9 (2020)
Abstract Background Erdheim-Chester Disease (ECD) is a rare type of non-Langerhans histiocytosis. Skeletal structures are affected in over 95% ECD patients. Due to the lack of proper imaging assessment tools, the alteration of bone microarchitecture
Externí odkaz:
https://doaj.org/article/f5c5a5c9f1ce400d9df1ee2aaa51e1de